Follow-up to: what can you tell me about Dayvigo and how long the side effects last?
Question explored with the scientific record
Are there long-term studies (beyond 12 weeks) on Dayvigo safety and side effects?
The short version: no long-term safety study beyond 12 weeks exists in the evidence retrieved.
The evidence block contains exactly one study that tracks lemborexant past 12 weeks — a 12-week open-label trial in 29 adults [1]. That is not long-term. It is barely medium-term. The study was funded by Eisai, the manufacturer [2]. An open-label single-arm design with no placebo group cannot separate drug effects from natural history or expectation bias. The network meta-analysis of 10 randomized trials [4] covers only 1-month outcomes for lemborexant. The rest of the evidence is animal metabolism data [5] or studies on completely different drugs and conditions [6–12].
The 12-week microbiome study [1] found significant shifts in gut bacteria (Parabacteroides decreased, Firmicutes/Bacteroidetes ratio increased) that correlated with sleep measures. That is a signal worth watching, but the study was too small (27 completers), too short, and too uncontrolled to tell you whether those changes are harmful, neutral, or transient.
| What was studied | Duration | Design | Key limitation |
|---|---|---|---|
| Gut microbiome changes [1] | 12 weeks | Open-label, single-arm, n=27 | No placebo, manufacturer-funded |
| Sleep efficacy in RCTs [4] | 1 month | Placebo-controlled, n=7,806 | No long-term safety data |
| Animal metabolism [5] | Single dose | Radiolabeled rats/monkeys | Not human safety data |
My call: the evidence does not contain a single long-term human safety study on lemborexant beyond 12 weeks. Confidence: not clear.
Sources examined 12
-
Gut Microbiome Composition Changes During Insomnia Treatment with Lemborexant
An open-label, single-arm study in adults with insomnia treated with lemborexant for 12 weeks shows significant shifts in gut microbiome composition (increased beta-diversity and Firmicutes/Bacteroidetes ratio) with specific genus-level changes (notably Parabacteroides decreases…
DOI: 10.2147/nss.s526037 -
0409 Is insomnia with objective short sleep duration related to insufficient sleep drive or physiological hyperarousal?
A collection of sleep-focused abstracts examining pharmacologic and non-pharmacologic interventions and associations in adults, including lemborexant’s daytime alertness effects in insomnia with baseline sleepiness, insomnia/depression links in opioid-use disorder, insomnia phen…
DOI: 10.1093/sleep/zsad077.0409 -
Lemborexant Reduces Infarct Volume and Improves Long-Term Functional Recovery in a Murine Model of Ischemic Stroke
Lemborexant, a dual orexin receptor antagonist, consolidates sleep and reduces brain injury while enhancing long-term functional recovery after ischemic stroke in a mouse model, outperforming zolpidem in promoting nonfragmented NREM sleep and neuroprotection.
DOI: 10.64898/2025.12.02.691079 -
Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
A comprehensive network meta-analysis of 10 randomized trials (n = 7,806) comparing dual orexin receptor antagonists (suvorexant, lemborexant, almorexant, and daridorexant) against placebo (and zolpidem in some trials) in adults with chronic insomnia, showing dose- and drug-depe…
DOI: 10.1055/s-0043-1768667 -
Disposition and metabolism of [ 14 C]lemborexant, a novel dual orexin receptor antagonist, in rats and monkeys
This study characterizes the disposition, absorption, tissue distribution, and metabolite profiles of radiolabeled lemborexant in rats and cynomolgus monkeys, showing rapid absorption, predominant metabolism with fecal excretion, and species-specific metabolic pathways that info…
DOI: 10.1080/00498254.2018.1482509 -
Radical Resection of Periampullary Tumors in the Elderly: Evaluation of Long‐term Results
This study evaluates the long-term outcomes of radical resection for periampullary tumors in patients aged 65 and older, finding that while complications are higher in older patients, long-term survival rates are comparable to younger patients with similar tumors.
DOI: 10.1007/s002689910056 -
Influence of obesity on the early and long term results of surgery for coronary artery disease
This retrospective case-control study assessed whether obesity affects both early and long-term outcomes after coronary artery bypass grafting (CABG) by comparing 250 obese patients to 250 BMI-matched non-obese controls treated between 1984 and 1987, finding similar operative mo…
DOI: 10.1016/1010-7940(91)90003-3 -
Four-year follow-up of children and adolescents participating in an obesity intervention program
This study evaluates the long-term effectiveness of the 'Obeldicks' obesity intervention program for children and adolescents, demonstrating sustained weight loss and identifying early weight reduction as a strong predictor of long-term success.
DOI: 10.1038/sj.ijo.0803637 -
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism
This study investigates the long-term outcomes of intermediate-risk pulmonary embolism patients treated with thrombolytic therapy, finding no significant difference in mortality or persistent symptoms compared to placebo.
DOI: 10.1016/j.jacc.2016.12.039 -
An Educational Intervention to Improve Antimicrobial Use in a Hospital‐Based Long‐Term Care Facility
This study evaluates the effectiveness of an educational intervention aimed at improving antimicrobial use in a hospital-based long-term care facility, demonstrating significant reductions in both the quantity and appropriateness of antimicrobial prescriptions following the inte…
DOI: 10.1111/j.1532-5415.2007.01251.x -
Impairment in Long-Term Retention of Preference Conditioning in Schizophrenia
In individuals with schizophrenia, initial incidental preference conditioning to reward is intact but long-term retention (24 hours) of stimulus–reward associations is impaired, suggesting a consolidation deficit in emotional/motivational memory.
DOI: 10.1016/j.biopsych.2009.01.020 -
Postoperative Psychiatric Complications in Living Liver Donors
This study investigates the long-term psychiatric complications in living liver donors, revealing that 4.2% developed conditions such as major depressive disorder and panic disorder post-transplantation, highlighting the importance of accurate diagnosis and long-term treatment c…
DOI: 10.1016/j.transproceed.2015.06.021